Komori
Other Disclosures4563AnGes,Inc.Pharmaceuticals

Notice of the Discontinuation of the Connected Gene Lab Gene+Connect Service

The online community platform つながる遺伝子ラボ Gene+Connect, jointly operated by アンジェス and クオン, will end on 30 June 2026. Information will continue to be provided through the corporate website and social media.

Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

つながる遺伝子ラボ Gene+Connect
Applicable field (uses covered by this announcement)

Promoting understanding of gene-related treatments and testing, and expanding support for the company's approach

Relationship between the counterparty and the company
AnGes,Inc.4563
Relationship with the Company

Joint operation

Counterpartyクオン株式会社

Head office: Minato-ku, Tokyo; Representative Director: Takeda Takashi (武田 隆)

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Announced details
ItemDetails
Names of Products / Services Coveredつながる遺伝子ラボ Gene+Connect
Counterpartyクオン株式会社
Counterparty overviewHead office: Minato-ku, Tokyo; Representative Director: Takeda Takashi (武田 隆)
Relationship with the CompanyJoint operation
Applicable areaPromoting understanding of gene-related treatments and testing, and expanding support for the company's approach
Items this document does not state (13)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The companies state that the platform has achieved a certain level of progress and will be brought to a close as they move forward with new initiatives aimed at its next stage of development.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Discontinuation of the Connected Gene Lab Gene+Connect Service | AnGes,Inc. (4563) timely disclosure | Komori